Gender | 0.60 |
Age (≥ 68 vs. < 67) | 0.89 |
KPS (≥ 80 |
0.38 |
Spine level (cervical |
0.74 |
Spine Level (cervical |
0.48 |
Spine Level (thoracic |
0.53 |
Paraspinal extension | 1.00 |
Dose per fraction (< 9 Gy v.s ≥ 9 Gy) | 0.43 |
Location (rigid/semi-rigid |
0.79 |
Mechanical pain | 0.79 |
Lytic |
0.93 |
Spinal alignment (normal |
0.96 |
Posterolateral involvement | 0.29 |
Location | ||||||
Junctional (O-C2; C7−T2; T11−L1; L5−S1) | 3 | 30% | 32 | 36% | 35 | 35% |
Mobile spine (C3−6; L2−4) | 3 | 30% | 18 | 20% | 21 | 21% |
Semirigid (T3−10) | 4 | 40% | 40 | 44% | 44 | 44% |
Rigid (S2−5) | 0 | 0% | 0 | 0% | 0 | 0% |
Mechanical pain | ||||||
Yes | 5 | 50% | 49 | 54% | 54 | 54% |
No | 3 | 30% | 30 | 33% | 33 | 33% |
Pain-free lesion | 2 | 20% | 11 | 12% | 13 | 13% |
Bone lesion | ||||||
Lytic | 8 | 80% | 71 | 79% | 79 | 79% |
Mixed (lytic/blastic) | 1 | 10% | 9 | 10% | 10 | 10% |
Blastic | 1 | 10% | 10 | 11% | 11 | 11% |
Radiographic spinal alignment | ||||||
Subluxation/translation present | 0 | 0% | 8 | 9% | 8 | 8% |
Deformity (kyphosis/scoliosis) | 2 | 20% | 17 | 19% | 19 | 19% |
Normal | 8 | 80% | 65 | 72% | 73 | 73% |
Vertebral body collapse (p = 0.040) | ||||||
> 50% collapse | 0 | 0% | 9 | 10% | 9 | 9% |
< 50% collapse | 1 | 10% | 8 | 9% | 9 | 9% |
No collapse with > 50% body involved | 1 | 10% | 38 | 42% | 39 | 39% |
None of the above | 8 | 80% | 35 | 39% | 43 | 43% |
Posterolateral involvement | ||||||
Bilateral | 0 | 0% | 5 | 6% | 5 | 5% |
Unilateral | 6 | 60% | 33 | 37% | 39 | 39% |
None of the above | 4 | 40% | 52 | 58% | 56 | 56% |
SINS classification | ||||||
Stable | 4 | 40% | 22 | 24% | 26 | 26% |
Potentially instability | 6 | 60% | 63 | 70% | 69 | 69% |
Unstable | 0 | 0% | 5 | 6% | 5 | 5% |
Median follow up, month (IQR) (n = 100) | 10.9 | 3.9–18.6 | 12.5 | 5.1–27.2 | 12.1 | 5.0–25.5 |
Sex (n = 83) |
||||||
Male | 5 | 56% | 37 | 50% | 42 | 51% |
Female | 4 | 44% | 37 | 50% | 41 | 49% |
Median age, year (IQR) (n = 83) |
67 | 63–70 | 69 | 59–75 | 68 | 59–74 |
Race (n = 83) | ||||||
White | 8 | 89% | 69 | 93% | 77 | 93% |
Black | 2 | 22% | 1 | 1% | 3 | 4% |
Other/unknown | 0 | 0% | 3 | 4% | 3 | 4% |
KPS (n = 83) |
||||||
≥ 80 | 9 | 90% | 70 | 95% | 79 | 95% |
< 80 | 1 | 10% | 3 | 4% | 4 | 5% |
Primary tumor (n = 100) |
||||||
Lung | 4 | 40% | 25 | 28% | 29 | 29% |
Renal | 1 | 10% | 23 | 26% | 24 | 24% |
Breast | 1 | 10% | 8 | 9% | 9 | 9% |
Prostate | 2 | 20% | 10 | 11% | 12 | 12% |
Melanoma | 0 | 0% | 2 | 2% | 2 | 2% |
Other | 2 | 20% | 22 | 24% | 24 | 24% |
Spine Level (n = 100) |
||||||
Cervical | 1 | 10% | 14 | 16% | 15 | 15% |
Thoracic | 6 | 60% | 58 | 64% | 64 | 64% |
Lumbosacral | 3 | 30% | 18 | 20% | 21 | 21% |
Kyphoplasty pre-SBRT (n = 100) |
||||||
Yes | 0 | 0% | 11 | 12% | 11 | 11% |
No | 10 | 100% | 79 | 88% | 89 | 89% |
Paraspinal extension (n = 100) |
||||||
Yes | 4 | 40% | 36 | 40% | 40 | 40% |
No | 6 | 60% | 54 | 60% | 60 | 60% |
Total dose (Gy)/fractions (n = 100) |
||||||
12−17/1 | 1 | 10% | 12 | 13% | 13 | 13% |
10−24/2 | 0 | 0% | 2 | 2% | 2 | 2% |
15−30/3 | 8 | 80% | 61 | 68% | 69 | 69% |
20-30/4–5 | 1 | 10% | 15 | 17% | 16 | 16% |
Dose (Gy) per fraction (n = 100) |
||||||
< 8 | 4 | 40% | 31 | 34% | 35 | 35% |
8−12 | 5 | 50% | 50 | 56% | 55 | 55% |
13−17 | 1 | 10% | 9 | 10% | 10 | 10% |